Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

被引:130
作者
del Alcazar, Carlos Rodrigo Gil [1 ]
Hardebeck, Molly Catherine [1 ]
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Gao, Xiaohuan [1 ]
Yan, Jingsheng [2 ]
Xie, Xian-Jin [2 ]
Bachoo, Robert [3 ]
Li, Li [3 ,4 ]
Habib, Amyn A. [3 ,4 ]
Burma, Sandeep [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金
美国国家航空航天局;
关键词
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; DEPENDENT PROTEIN-KINASE; RAPAMYCIN INHIBITOR; PRECLINICAL EVALUATION; ADJUVANT TEMOZOLOMIDE; DAMAGE RESPONSE; CANCER-CELLS; IN-VIVO; ATM; RADIOTHERAPY;
D O I
10.1158/1078-0432.CCR-13-1607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文
共 50 条
  • [31] EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma
    Mukherjee, Bipasha
    McEllin, Brian
    Camacho, Cristel V.
    Tomimatsu, Nozomi
    Sirasanagandala, Shyam
    Nannepaga, Suraj
    Hatanpaa, Kimmo J.
    Mickey, Bruce
    Madden, Christopher
    Maher, Elizabeth
    Boothman, David A.
    Furnari, Frank
    Cavenee, Webster K.
    Bachoo, Robert M.
    Burma, Sandeep
    [J]. CANCER RESEARCH, 2009, 69 (10) : 4252 - 4259
  • [32] Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
    Munck, Joanne M.
    Batey, Michael A.
    Zhao, Yan
    Jenkins, Helen
    Richardson, Caroline J.
    Cano, Celine
    Tavecchio, Michele
    Barbeau, Jody
    Bardos, Julia
    Cornell, Liam
    Griffin, Roger J.
    Menear, Keith
    Slade, Andrew
    Thommes, Pia
    Martin, Niall M. B.
    Newell, David R.
    Smith, Graeme C. M.
    Curtin, Nicola J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (08) : 1789 - 1798
  • [33] Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
    Muranen, Taru
    Selfors, Laura M.
    Worster, Devin T.
    Iwanicki, Marcin P.
    Song, Loling
    Morales, Fabiana C.
    Gao, Sizhen
    Mills, Gordon B.
    Brugge, Joan S.
    [J]. CANCER CELL, 2012, 21 (02) : 227 - 239
  • [34] Papadopoulos MC, 2001, BRIT J NEUROSURG, V15, P101
  • [35] LOSS OF THE CATALYTIC SUBUNIT OF THE DNA-DEPENDENT PROTEIN-KINASE IN DNA DOUBLE-STRAND-BREAK-REPAIR MUTANT MAMMALIAN-CELLS
    PETERSON, SR
    KURIMASA, A
    OSHIMURA, M
    DYNAN, WS
    BRADBURY, EM
    CHEN, DJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) : 3171 - 3174
  • [36] A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
    Peyton, J. D.
    Ahnert, J. Rodon
    Burris, H.
    Britten, C.
    Chen, L. C.
    Tabernero, J.
    Duval, V.
    Rouyrre, N.
    Silva, A. P.
    Quadt, C.
    Baselga, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Opposing Effect of EGFRWT on EGFRvIII-Mediated NF-κB Activation with RIP1 as a Cell Death Switch
    Puliyappadamba, Vineshkumar Thidil
    Chakraborty, Sharmistha
    Chauncey, Sandili S.
    Li, Li
    Hatanpaa, Kimmo J.
    Mickey, Bruce
    Noorani, Shayan
    Shu, Hui-Kuo G.
    Burma, Sandeep
    Boothman, David A.
    Habib, Amyn A.
    [J]. CELL REPORTS, 2013, 4 (04): : 764 - 775
  • [38] Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
    Roos, W. P.
    Batista, L. F. Z.
    Naumann, S. C.
    Wick, W.
    Weller, M.
    Menck, C. F. M.
    Kaina, B.
    [J]. ONCOGENE, 2007, 26 (02) : 186 - 197
  • [39] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
    Santiskulvong, Chintda
    Konecny, Gottfried E.
    Fekete, Mirela
    Chen, Kuang-Yui Michael
    Karam, Amer
    Mulholland, David
    Eng, Carol
    Wu, Hong
    Song, Min
    Dorigo, Oliver
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2373 - 2384
  • [40] Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:: Implications for clinical imaging
    Schnell, Christian R.
    Stauffer, Frederic
    Allegrini, Peter R.
    O'Reilly, Terence
    McSheehy, Paul M. J.
    Dartois, Celine
    Stumm, Michael
    Cozens, Robert
    Littlewood-Evans, Amanda
    Garcia-Echeverria, Carlos
    Maira, Sauveur-Michel
    [J]. CANCER RESEARCH, 2008, 68 (16) : 6598 - 6607